Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting
October 11, 2023 08:00 ET
|
Elicio Therapeutics Inc.
BOSTON, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer
September 27, 2023 17:30 ET
|
Elicio Therapeutics Inc.
ELI-002 2P is an investigational therapeutic cancer vaccine targeting solid tumors driven by G12D and G12R mutations in KRASAs of the April 25, 2023 data cut-off date, among the 22 evaluable patients,...
Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines
September 07, 2023 08:00 ET
|
Elicio Therapeutics Inc.
Funds will advance research into ELI-007, a mutant BRAF-peptide vaccine, and ELI-008, a p53 hotspot mutation-peptide vaccine, with the aim of developing multivalent cancer vaccines targeting several...
Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 08:00 ET
|
Elicio Therapeutics Inc.
BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic Cancer
September 05, 2023 08:00 ET
|
Elicio Therapeutics Inc.
BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel...
Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics
August 28, 2023 08:00 ET
|
Elicio Therapeutics Inc.
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer,...
Elicio Therapeutics Reports Inducement Grants
August 22, 2023 16:30 ET
|
Elicio Therapeutics Inc.
BOSTON, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today...
Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
August 11, 2023 08:30 ET
|
Elicio Therapeutics Inc.
ELI-002 2P positive interim data from AMPLIFY-201 Phase 1 study presented at ASCOAMPLIFY-7P first patient dosed with ELI-002 7P Completed reverse merger becoming a publicly traded company on Nasdaq...
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating AMP-CpG Adjuvant Can Induce Potent and Durable Immune Response in Epstein-Barr Virus (EBV) Infectious Disease Model
August 09, 2023 08:00 ET
|
Elicio Therapeutics Inc.
AMP-CpG directed vaccine to lymph nodes inducing broad humoral and cellular immunity against multiple viral determinants expressed during the EBV life cycle AMP-CpG immunization generated persistent...
Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split
June 01, 2023 08:00 ET
|
Angion Biomedica Corp.
NEWTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Angion Biomedia Corp. (NASDAQ: ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel...